http://www.xconomy.com/seattle/2009/08/12/seattle-genetics-bucking-the-trend-recruits-hodgkins-patients-at-warp-speed/ Business + Technology in the Exponential Economy Sat, 11 Feb 2012 09:14:03 +0000 hourly 1 http://wordpress.org/?v=3.0.4 http://www.xconomy.com/seattle/2009/08/12/seattle-genetics-bucking-the-trend-recruits-hodgkins-patients-at-warp-speed/comment-page-1/#comment-74714 Seattle Genetics ahead of schedule with cancer drug - FierceBiotech Wed, 12 Aug 2009 15:38:55 +0000 http://www.xconomy.com/?p=36866#comment-74714 [...] Most biotech and pharma companies struggle to enroll patients in clinical trials, but not Seattle Genetics. The company, which is testing an antibody to treat Hodgkin's disease, is enrolling trials of the drug so quickly that it's six months ahead of schedule, according to a piece in Xconomy. The company now says that its brentuximab vedotin (previously known as SGN-35) could reach the market as early as 2011. Report [...] [...] Most biotech and pharma companies struggle to enroll patients in clinical trials, but not Seattle Genetics. The company, which is testing an antibody to treat Hodgkin’s disease, is enrolling trials of the drug so quickly that it’s six months ahead of schedule, according to a piece in Xconomy. The company now says that its brentuximab vedotin (previously known as SGN-35) could reach the market as early as 2011. Report [...]

]]>